TABLE 2
FROM:
Hospitalized avascular necrosis after renal transplantation in the United States
Kevin C Abbott, Robert J Oglesby and Lawrence Y Agodoa
BACK TO ARTICLETable 2. Categorical variables of renal transplant recipients hospitalized for avascular necrosis (AVN) versus all other renal transplant recipients, July 1, 1994–June 30, 1998a , b
| Unadjusted HR | Adjusted HR | |||
|---|---|---|---|---|
| Factor | Renal transplant recipients | Missing, N (%) | for AVN | |
| N | 42,096 | |||
| Male recipient | 23,827 (60.1) | 0 | ||
| African American | 9142 (23.1) | 640 (1.5) | 1.52 (1.27–1.82) | 1.65 (1.33–2.03) |
| Graft loss | 2815 (6.5%) | 0 | ||
| Cadaveric donor | 27,369 (69.1) | 0 | ||
| History of peritoneal dialysis (vs. hemodialysis) | 8260 (19.6) | 7855 (18.7) | 1.34 (1.11–1.63) | 1.44 (1.15–1.81) |
| Recipient HCV positive | 2198 (5.6) | 5743 (13.6) | ||
| Donor CMV positive | 23,552 (57.1) | 1620 (3.8) | ||
| More recent year of transplant (compared with 1994) | 0 | |||
| Dialysis in the first week post-transplant | 7682 (18.5) | 2382 (5.7) | ||
| Rejection | 8335 (19.8) | 0 | 1.58 (1.28–1.95) | 1.67 (1.35–2.07) |
| Cause of ESRD (vs. all others) | ||||
| Diabetes | 7862 (19.7) | 5178 (12.3) | 0.31 (0.21–0.47) | 0.41 (0.27–0.64) |
| Systemic lupus erythematosus | 1329 (3.2) | 5178 (12.3) | ||
| Maintenance medications (each medication vs. all others) | ||||
| Cyclosporine | 31,448 (74.7) | 3372 (8) | 1.79 (1.43–2.24) | |
| Tacrolimus | 4623 (11.9) | 3372 (8) | 0.49 (0.35–0.70) | |
| Mycophenolate | 18,608 (47.9) | 3221 (7.6) | ||
| Azathioprine | 16,308 (41.9) | 3157 (7.5) | 1.22 (1.03–1.45) | |
| Prednisone | 34,451 (90.1) | 3880 (9.2) | ||
| Induction antibody therapy | 11,905 (28.3) | 2277 (5.4) | ||
Data are given as the number (% of total) mean 
one standard deviation. Abbreviations are: HR, hazard ratios; AVN, hospitalization for avascular necrosis; defined as ICD9 code 733.4x; HCV, hepatitis C virus; CMV, cytomegalovirus; ESRD = end-stage renal disease.
a Follow-up time truncated at three years post transplant
b P < 0.01 vs. all other recipients by Chi square test vs. recipients without AVN
